$750 Million Deal Paves the Way for Brains Bioceutical Nasdaq Listing
Key Facts
Armada Acquisition Corp. III and Brains Bioceutical signed a definitive business combination agreement on October 31, 2026, and announced it on November 5, in a deal that paves the way for the pharmaceutical company to list on Nasdaq. The company’s statement described an implied pre-financing equity value of about $750 million, while the business combination agreement provides for an enterprise value used primarily to calculate consideration after specified adjustments. The different descriptions reflect distinct valuation bases, so the enterprise value does not necessarily represent the amount shareholders will receive. The agreement also provides that eligible outstanding shares will convert at an exchange ratio calculated based on the transaction value and the number of shares on a fully diluted basis. The combined company is expected to operate as Brains Therapeutics Corp., with its common stock trading on Nasdaq under the ticker BAPI after the deal closes.
The parties are seeking to arrange financing for the deal with gross proceeds of up to $100 million through closing, according to Armada’s filing with the U.S. Securities and Exchange Commission. The potential financing adds a source of cash to the deal, but the filing sets a target cap and does not confirm that the full amount has already been raised. Separately from the financing, the latest quarterly data available before the announcement showed that Armada’s trust account held $251,572,228 in cash and marketable securities on June 30, 2026. That balance puts the pre-announcement liquidity picture in context, before any redemptions or financing. The funds that will remain available after closing also depend on closing conditions and the level of redemptions.
The agreement provides for the issuance of 14,705,882 additional shares to Brains shareholders at closing, to be held in escrow. Half of those shares will be released if the stock reaches a threshold of $12.50, and the other half at $15. Each threshold is tied to a volume-weighted price test, requiring it to be met on at least 20 trading days within any consecutive 30-trading-day period. The additional shares therefore will not all be issued immediately at closing; their release depends on meeting specified price conditions over a defined measurement period. This mechanism forms part of the potential consideration for shareholders and could increase the number of outstanding shares if the stated conditions are met.
Brains operates in life sciences and pharmaceuticals, with activities that include manufacturing and supplying active pharmaceutical ingredients, pharmaceutical research and drug development, according to the company statement accompanying the filing. The company says it operates an active pharmaceutical ingredient manufacturing facility in the English county of Kent through its BSPG Laboratories unit. It added that the facility is inspected and registered with the U.K. Medicines and Healthcare products Regulatory Agency. Brains says its plans include expanding the manufacture and supply of cannabis active pharmaceutical ingredients, alongside advancing its proprietary and partnered drug development programs. These remain stated company objectives, while a potential listing would provide a route for its shares to trade on the public market after the deal closes.
The deal comes as Armada, a recently formed special purpose acquisition company, completed its initial public offering on February 19, 2026, selling 24,850,000 units at $10 per unit, according to its quarterly report. Since the offering, the company has deposited funds in a trust account, which held about $251.6 million in cash and marketable securities on June 30, 2026. The trust balance and the financing the parties are seeking to arrange are separate elements in the picture of potential resources for the deal. The amount available after closing will depend on completing the contractual conditions and on redemptions, as well as any financing that may be arranged. The trust balance alone does not establish how much money will remain for the combined company after these transactions.
Closing the deal requires approval from shareholders of both parties and orders from the Supreme Court of British Columbia, as well as the effectiveness of the registration statement and Nasdaq’s approval of the listing. The agreement also requires combined net tangible assets of at least $5,000,001 after the deal, financing and redemptions. The parties are targeting a closing in the second quarter of 2027, according to the filing and the company statement. Either party may terminate the agreement if the deal has not closed by June 30, 2027, subject to its terms. Until then, approvals, meeting the asset requirement and completing financing arrangements remain necessary steps before the combined company’s common stock begins trading under the ticker BAPI.